Synthetic Biologics, Inc. (NYSEMKT:SYN)
CAPS Rating:
A development-stage, specialty pharmaceutical company that is developing proprietary, late-stage drug candidates for the treatment of neurologic and fibrotic diseases.
A development-stage, specialty pharmaceutical company that is developing proprietary, late-stage drug candidates for the treatment of neurologic and fibrotic diseases.
Recs
Losing money.